Ascendis Pharma A/S (ASND) to Release Earnings on Wednesday

Ascendis Pharma A/S (NASDAQ:ASND) will likely be posting its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect Ascendis Pharma A/S to post earnings of ($0.49) per share and revenue of $246.9130 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million for the quarter, compared to analysts’ expectations of $163.17 million. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ascendis Pharma A/S Stock Down 0.8%

Shares of NASDAQ:ASND opened at $197.74 on Monday. Ascendis Pharma A/S has a fifty-two week low of $118.03 and a fifty-two week high of $216.45. The firm’s 50-day simple moving average is $201.67 and its 200-day simple moving average is $183.54. The company has a market cap of $12.20 billion, a price-to-earnings ratio of -38.32 and a beta of 0.44.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC acquired a new stake in Ascendis Pharma A/S in the 2nd quarter valued at about $166,367,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Ascendis Pharma A/S by 40.4% in the second quarter. Adage Capital Partners GP L.L.C. now owns 459,606 shares of the biotechnology company’s stock valued at $79,328,000 after purchasing an additional 132,201 shares in the last quarter. Qube Research & Technologies Ltd grew its position in shares of Ascendis Pharma A/S by 83.4% in the second quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company’s stock valued at $34,700,000 after purchasing an additional 91,412 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Ascendis Pharma A/S by 33.2% during the 2nd quarter. Vestal Point Capital LP now owns 200,000 shares of the biotechnology company’s stock worth $34,520,000 after purchasing an additional 49,858 shares in the last quarter. Finally, Orbimed Advisors LLC acquired a new position in shares of Ascendis Pharma A/S during the 2nd quarter worth approximately $5,937,000.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ASND. JPMorgan Chase & Co. lifted their price objective on Ascendis Pharma A/S from $260.00 to $264.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. UBS Group reissued a “buy” rating and issued a $307.00 price target (up from $306.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Raymond James Financial initiated coverage on Ascendis Pharma A/S in a report on Friday, October 17th. They set a “strong-buy” rating and a $271.00 price objective on the stock. Cantor Fitzgerald increased their price objective on Ascendis Pharma A/S from $203.00 to $254.00 and gave the stock an “overweight” rating in a research report on Monday, October 13th. Finally, Wedbush raised their target price on Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an “outperform” rating in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and an average target price of $249.80.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.